Q J Med 1999; 92: 187-192
© 1999 Association of Physicians
Review |
The management of hypertensive disease in Black patients
From the University Department of Medicine, and Department of Cardiology, City Hospital, Birmingham, UK
Dr G.Y.H. Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH. e-mail: g.y.h.lip{at}bham.ac.uk
The ethnic differences in the incidence, pathophysiology and management of hypertensive disease, are particularly pertinent to the Black or Afro-Caribbean populations, who have a high prevalence of hypertension and associated complications, such as strokes and renal impairment. Our understanding of the underlying pathophysiology of hypertensive disease and the optimal treatment of hypertension in Black patients continues to evolve, especially with the introduction of new drugs and the need for prognostic data in this ethnic population. We review the management of hypertensive disease in the black population, emphasizing race-related differences in the pathophysiology of hypertension and the importance of tailored management in this group of patients, including sensible application of non-pharmacological measures with effective antihypertensive agents. For example, diuretics and calcium antagonists are suitable first-line agents in black hypertensives, whilst beta-blockers and the ACE inhibitors tend to be less effective at lowering blood pressure, due to the low renin state in these patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Calhoun, Y. Lacourciere, Y. T. Chiang, and R. D. Glazer Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial Hypertension, July 1, 2009; 54(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. De, G. Das, K. Harley, and H. Nair Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A Heckman Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Evid. Based Med., November 1, 2003; 8(6): 168 - 168. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.A. Lane and G.Y.H. Lip Ethnic differences in hypertension and blood pressure control in the UK QJM, July 1, 2001; 94(7): 391 - 396. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wilding, G. Williams, G. Drummond, T. Marshall, A. Rouse, J. Eisenberg, A. Hey, T. A Chowdhury, H. Sandvik, M. Stewart, et al. Management of hypertension BMJ, February 26, 2000; 320(7234): 576 - 576. [Full Text]
|
|
|
|
|
|
T.O. Cheng Hypertensive disease in Black patients QJM, August 1, 1999; 92(8): 481 - 481. [Full Text] [PDF]
|
|